poisar

Stocks · News reference

Arrowhead Pharmaceuticals Presents Plozasiran Data at AHA Scientific Sessions 2026

Fiscal.ai

Arrowhead Pharmaceuticals presented new clinical data for its RNAi-based cardiometabolic therapies, including plozasiran, at the American Heart Association Scientific Sessions 2026.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading